Titre : Neuroblastome

Neuroblastome : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cell Line, Tumor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Neuroblastome : Questions médicales les plus fréquentes", "headline": "Neuroblastome : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Neuroblastome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-31", "dateModified": "2024-12-26", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Neuroblastome" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs neuroectodermiques primitives périphériques", "url": "https://recherchemedicale.com/mesh/D018241", "about": { "@type": "MedicalCondition", "name": "Tumeurs neuroectodermiques primitives périphériques", "code": { "@type": "MedicalCode", "code": "D018241", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.580.625.600.590.650" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ganglioneuroblastome", "alternateName": "Ganglioneuroblastoma", "url": "https://recherchemedicale.com/mesh/D018305", "about": { "@type": "MedicalCondition", "name": "Ganglioneuroblastome", "code": { "@type": "MedicalCode", "code": "D018305", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.557.580.625.600.590.650.550.300" } } } ], "about": { "@type": "MedicalCondition", "name": "Neuroblastome", "alternateName": "Neuroblastoma", "code": { "@type": "MedicalCode", "code": "D009447", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Anna Rita Gigliotti", "url": "https://recherchemedicale.com/author/Anna%20Rita%20Gigliotti", "affiliation": { "@type": "Organization", "name": "Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy." } }, { "@type": "Person", "name": "Giovanni Erminio", "url": "https://recherchemedicale.com/author/Giovanni%20Erminio", "affiliation": { "@type": "Organization", "name": "Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy." } }, { "@type": "Person", "name": "Bruno De Bernardi", "url": "https://recherchemedicale.com/author/Bruno%20De%20Bernardi", "affiliation": { "@type": "Organization", "name": "Oncology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy." } }, { "@type": "Person", "name": "Rui Dong", "url": "https://recherchemedicale.com/author/Rui%20Dong", "affiliation": { "@type": "Organization", "name": "Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China." } }, { "@type": "Person", "name": "Giuseppe Martucciello", "url": "https://recherchemedicale.com/author/Giuseppe%20Martucciello", "affiliation": { "@type": "Organization", "name": "Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Largo Gaslini 5, 16147, Genoa, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Purine Nucleotide Alterations in Tumoral Cell Lines Maintained with Physiological Levels of Folic Acid.", "datePublished": "2023-08-08", "url": "https://recherchemedicale.com/article/37628755", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms241612573" } }, { "@type": "ScholarlyArticle", "name": "Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.", "datePublished": "2023-05-02", "url": "https://recherchemedicale.com/article/37131108", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11060-023-04308-4" } }, { "@type": "ScholarlyArticle", "name": "HLA-G neo-expression modifies genetic programs governing tumor cell lines.", "datePublished": "2024-10-03", "url": "https://recherchemedicale.com/article/39358558", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00262-024-03768-5" } }, { "@type": "ScholarlyArticle", "name": "Connexin Expression in Pituitary Adenomas and the Effects of Overexpression of Connexin 43 in Pituitary Tumor Cell Lines.", "datePublished": "2022-04-12", "url": "https://recherchemedicale.com/article/35456480", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/genes13040674" } }, { "@type": "ScholarlyArticle", "name": "Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines.", "datePublished": "2022-11-30", "url": "https://recherchemedicale.com/article/36447028", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12640-022-00606-3" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Recherchemedicale.com", "item": "https://recherchemedicale.com" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://recherchemedicale.com/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs par type histologique", "item": "https://recherchemedicale.com/mesh/D009370" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs du tissu nerveux", "item": "https://recherchemedicale.com/mesh/D009380" }, { "@type": "ListItem", "position": 5, "name": "Tumeurs neuroectodermiques", "item": "https://recherchemedicale.com/mesh/D017599" }, { "@type": "ListItem", "position": 6, "name": "Tumeurs neuroépitheliales", "item": "https://recherchemedicale.com/mesh/D018302" }, { "@type": "ListItem", "position": 7, "name": "Tumeurs neuroectodermiques primitives", "item": "https://recherchemedicale.com/mesh/D018242" }, { "@type": "ListItem", "position": 8, "name": "Tumeurs neuroectodermiques primitives périphériques", "item": "https://recherchemedicale.com/mesh/D018241" }, { "@type": "ListItem", "position": 9, "name": "Neuroblastome", "item": "https://recherchemedicale.com/mesh/D009447" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Neuroblastome - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Neuroblastome", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-02-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Neuroblastome", "description": "Comment diagnostique-t-on un neuroblastome ?\nQuels tests d'imagerie sont utilisés ?\nQuels marqueurs sanguins sont associés au neuroblastome ?\nLe neuroblastome peut-il être confondu avec d'autres maladies ?\nQuel rôle joue la biopsie dans le diagnostic ?", "url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Cell+Line,+Tumor&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Neuroblastome", "description": "Quels sont les symptômes courants du neuroblastome ?\nLe neuroblastome peut-il causer des symptômes neurologiques ?\nComment se manifeste le neuroblastome chez les nourrissons ?\nY a-t-il des symptômes spécifiques selon l'âge ?\nLe neuroblastome peut-il provoquer des symptômes respiratoires ?", "url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Cell+Line,+Tumor&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Neuroblastome", "description": "Peut-on prévenir le neuroblastome ?\nY a-t-il des facteurs de risque identifiés ?\nLes antécédents familiaux influencent-ils le risque ?\nLes infections virales sont-elles un facteur de risque ?\nL'exposition à des produits chimiques augmente-t-elle le risque ?", "url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Cell+Line,+Tumor&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Neuroblastome", "description": "Quels sont les traitements standards pour le neuroblastome ?\nLa chirurgie est-elle toujours nécessaire ?\nQu'est-ce que l'immunothérapie pour le neuroblastome ?\nQuels effets secondaires peuvent survenir avec la chimiothérapie ?\nLe traitement du neuroblastome varie-t-il selon le stade ?", "url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Cell+Line,+Tumor&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Neuroblastome", "description": "Quelles complications peuvent survenir avec le neuroblastome ?\nLe neuroblastome peut-il affecter d'autres organes ?\nComment les traitements peuvent-ils causer des complications ?\nY a-t-il des complications à long terme ?\nLes complications psychologiques sont-elles possibles ?", "url": "https://recherchemedicale.com/mesh/D009447?mesh_terms=Cell+Line,+Tumor&page=2#section-complications" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on un neuroblastome ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des examens d'imagerie, des biopsies et des analyses sanguines." } }, { "@type": "Question", "name": "Quels tests d'imagerie sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les échographies, IRM et TEP-scan sont couramment utilisés pour visualiser la tumeur." } }, { "@type": "Question", "name": "Quels marqueurs sanguins sont associés au neuroblastome ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les niveaux de la dopamine et de la vanillylmandélique acid (VMA) peuvent être élevés." } }, { "@type": "Question", "name": "Le neuroblastome peut-il être confondu avec d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut être confondu avec d'autres tumeurs pédiatriques ou maladies neurologiques." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet de confirmer la présence de cellules tumorales et de déterminer le type de tumeur." } }, { "@type": "Question", "name": "Quels sont les symptômes courants du neuroblastome ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des masses abdominales et des ecchymoses." } }, { "@type": "Question", "name": "Le neuroblastome peut-il causer des symptômes neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut entraîner des symptômes neurologiques comme des troubles de la marche ou des convulsions." } }, { "@type": "Question", "name": "Comment se manifeste le neuroblastome chez les nourrissons ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Chez les nourrissons, il peut se manifester par une masse abdominale et des troubles de l'alimentation." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques selon l'âge ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier selon l'âge, avec des manifestations plus sévères chez les jeunes enfants." } }, { "@type": "Question", "name": "Le neuroblastome peut-il provoquer des symptômes respiratoires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, si la tumeur se développe dans la région thoracique, elle peut causer des difficultés respiratoires." } }, { "@type": "Question", "name": "Peut-on prévenir le neuroblastome ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de méthodes connues pour prévenir le neuroblastome." } }, { "@type": "Question", "name": "Y a-t-il des facteurs de risque identifiés ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs génétiques et environnementaux peuvent augmenter le risque de neuroblastome." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un antécédent familial de neuroblastome peut augmenter le risque chez les enfants." } }, { "@type": "Question", "name": "Les infections virales sont-elles un facteur de risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales ont été étudiées, mais leur lien avec le neuroblastome reste incertain." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques augmente-t-elle le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent que l'exposition à certains produits chimiques pourrait être un facteur de risque." } }, { "@type": "Question", "name": "Quels sont les traitements standards pour le neuroblastome ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie, la radiothérapie et l'immunothérapie." } }, { "@type": "Question", "name": "La chirurgie est-elle toujours nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, cela dépend de la taille et de l'emplacement de la tumeur ainsi que de son stade." } }, { "@type": "Question", "name": "Qu'est-ce que l'immunothérapie pour le neuroblastome ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'immunothérapie utilise le système immunitaire pour cibler et détruire les cellules cancéreuses." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir avec la chimiothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent la fatigue, les nausées, la perte de cheveux et les infections." } }, { "@type": "Question", "name": "Le traitement du neuroblastome varie-t-il selon le stade ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le traitement est adapté en fonction du stade de la maladie et de la réponse au traitement." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le neuroblastome ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la propagation de la maladie, des infections et des effets secondaires des traitements." } }, { "@type": "Question", "name": "Le neuroblastome peut-il affecter d'autres organes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut se propager aux os, au foie et à d'autres organes, entraînant des complications graves." } }, { "@type": "Question", "name": "Comment les traitements peuvent-ils causer des complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements comme la chimiothérapie peuvent affaiblir le système immunitaire et causer des infections." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent développer des complications à long terme, comme des problèmes de croissance." } }, { "@type": "Question", "name": "Les complications psychologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les enfants peuvent éprouver des complications psychologiques, comme l'anxiété et la dépression." } } ] } ] }

Sources (10000 au total)

Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.

Tumor Treating Fields (TTFields) are electric fields that disrupt cellular processes critical for cancer cell viability and tumor progression, ultimately leading to cell death. TTFields therapy is app... Human GBM cell lines with different MGMT promoter methylation statuses were treated with TTFields, TMZ, and CCNU, and effectiveness was tested by cell count, apoptosis, colony formation, and DNA damag... TTFields concomitant with TMZ displayed an additive effect, irrespective of MGMT expression levels. TTFields concomitant with CCNU or with CCNU plus TMZ was additive in MGMT-expressing cells and syner... The results support the clinical benefit demonstrated for TTFields concomitant with TMZ plus CCNU. Since the FA-BRCA pathway is required for repair of DNA cross-links induced by CCNU in the absence of...

The anticancer effects of Metformin in the male germ tumor SEM-1 cell line are mediated by HMGA1.

Germ cell tumors (GCTs) are the most common type of cancer in young men. These tumors usually originate from the testis, but they can occasionally develop from extragonadal sites probably due to primo... SEM-1 cells, a newly established human cell line of extragonadal origin, were treated with Met. Cell viability was studied by MTT assay, while cell migration and invasion were studied by the wound hea... Treatment of SEM-1 cells with Met resulted in a potent and dose-dependent reduction of cell proliferation, as evidenced by decreased nuclear abundance of cyclin D1 and cell cycle arrest in G1 phase. A... Our results document the antiproliferative and antimigratory effects of Met in SEM-1 cells, providing new insights into the potential treatments for male GCTs. The anticancer properties of Met in SEM-...

The Effect of MicroRNA-409-3p for Treatment and Response to Tumor Proliferation of Lung Cancer Cell Lines (In Vitro).

Monitoring the result of miR 409 3p and its response to tumor proliferation and its mechanism of action on some types of lung cancer in vitro (A549 cell line).... Two A549 cell line group negative control group with oligonucleotide cultured under conventional conditions and transfected with positive control nucleotides. Experiments Based on the control group, c... miR4093p expression was estimated using the qPCR method in the two groups after 48 h. Later, the miR-409-3p expression in A549 cells obviously increased significantly with a positive attitude in the p... miR-409-3p may prevent non-small cell lung cancer (NSCLC) by affecting ELF2 transcription and other cellular regulators to regulate A549 cell division and induce apoptosis....

Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line.

Clinical control of corticotroph tumors is difficult to achieve since they usually persist or relapse after surgery. Pasireotide is approved to treat patients with Cushing's disease for whom surgical ... It was assessed cell viability, POMC expression and ACTH secretion in AtT20/D16v-F2 cells over- or under-expressing PRKCD.... We found that Pasireotide significantly reduces AtT20/D16v-F2 cell viability, POMC expression and ACTH secretion. In addition, Pasireotide reduces miR-26a expression. PRKCD silencing decreases AtT20/D... Our results provide new insights into potential PRKCD contribution in Pasireotide mechanism of action and suggest that PRKCD might be a possible marker of therapeutic response in ACTH-secreting pituit...